The class I multi-kinase inhibitors include midostaurin, gilteritinib, and crenolanib, among which only midostaurin has been FDA and EMA (European Medicines Agencies)-approved for treatment of AML patients with activating FLT3 mutations (in combination with cytarabine and daunorubicin) [40]. The gene discussed is FLT3; the disease is acute myeloid leukemia.